Taysha Gene Therapies, Inc. Other Nonoperating Expense
Taysha Gene Therapies, Inc. (TSHA) reported Other Nonoperating Expense of $8.00 thousand for the 3-month period ending 2023-03-31, per its 10-Q filed 2023-05-11.
Discontinued › Income Statement › Other Income
us-gaap:OtherNonoperatingExpense · last filed 2023-05-11
- Taysha Gene Therapies, Inc. other nonoperating expense for the quarter ending 2023-03-31 was $8.00K, a 0.00% change year-over-year.
- Taysha Gene Therapies, Inc. other nonoperating expense for the quarter ending 2022-12-31 was $6.00K.
- Taysha Gene Therapies, Inc. other nonoperating expense for the quarter ending 2022-09-30 was $1.00K.
- Taysha Gene Therapies, Inc. other nonoperating expense for the quarter ending 2022-06-30 was $3.00K.
- Taysha Gene Therapies, Inc. other nonoperating expense for fiscal 2022 was $18.00K.
| Period end | Other Nonoperating Expense 3 month | Other Nonoperating Expense 6 month | Other Nonoperating Expense 9 month | Other Nonoperating Expense 12 month |
|---|---|---|---|---|
| 2023-03-31 | $8.00K 10-Q · filed 2023-05-11 | $14.00K derived: sum of 2 quarters · filed 2023-05-11 | $15.00K derived: sum of 3 quarters · filed 2023-05-11 | $18.00K derived: sum of 4 quarters · filed 2023-05-11 |
| 2022-12-31 | $6.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-28 | $7.00K derived: sum of 2 quarters · filed 2023-03-28 | $10.00K derived: sum of 3 quarters · filed 2023-03-28 | $18.00K 10-K · filed 2023-03-28 |
| 2022-09-30 | $1.00K 10-Q · filed 2022-11-08 | $4.00K derived: sum of 2 quarters · filed 2022-11-08 | $12.00K 10-Q · filed 2022-11-08 | |
| 2022-06-30 | $3.00K 10-Q · filed 2022-08-11 | $11.00K 10-Q · filed 2022-08-11 | ||
| 2022-03-31 | $8.00K 10-Q · filed 2023-05-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Immunocore Holdings plc (IMCR) | $1.613B | -90.43 | |
| Inhibrx Biosciences, Inc. (INBX) | United States | $1.477B | -10.08 |
| Maze Therapeutics, Inc. (MAZE) | United States | $1.457B | -12.40 |
| Hemab Therapeutics Holdings, Inc. (COAG) | United States | $1.672B | |
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |
| Vir Biotechnology, Inc. (VIR) | United States | $1.814B | -6.85 |
| Replimune Group, Inc. (REPL) | United States | $1.186B | -3.13 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Vor Biopharma Inc. (VOR) | United States | $1.091B | 1.60 |
| MeiraGTx Holdings plc (MGTX) | United States | $1.061B | 16.10 |